Perinatal mortality from Rh(D) hemolytic disease in Finland, 1975-1984

Area of Science:

• Immunology
• Obstetrics
• Perinatology

Background:

• Rh(D) hemolytic disease of the newborn (HDN) remains a concern despite widespread anti-D immunoglobulin (IgG) prophylaxis.
• Finnish anti-D programs, implemented in 1969 (postnatal) and 1971 (post-abortion), have reduced HDN incidence but not eliminated perinatal mortality.
• Analysis of recent HDN deaths was conducted to identify remaining immunization pathways.

Purpose of the Study:

• To investigate the causes of death from Rh(D) hemolytic disease (HDN) in Finland over the past decade.
• To identify failures or gaps in the existing anti-D immunoglobulin prophylaxis program.
• To determine strategies for further reducing HDN-related mortality.

Main Methods:

• Retrospective analysis of 41 deaths attributed to Rh(D) hemolytic disease (HDN) in Finland over a 10-year period.
• Categorization of deaths based on the timing and presumed cause of maternal Rh(D) immunization.
• Review of the effectiveness and potential shortcomings of the national anti-D IgG program.

Main Results:

• Of 41 deaths, 17 occurred in mothers immunized before anti-D IgG was available, and 3 from prior blood transfusions.
• Nine deaths were linked to program loopholes, potentially preventable with universal postnatal/post-abortion anti-D IgG.
• Six deaths resulted from first-trimester immunization, and three from immunization despite anti-D IgG administration.

Conclusions:

• Complete eradication of Rh(D) hemolytic disease (HDN) may not be achievable with current strategies.
• Antenatal and postnatal anti-D IgG administration is crucial to minimize immunization from first pregnancies and transfusion.
• Addressing loopholes in the anti-D program and ensuring universal coverage are essential to further reduce HDN mortality.